Analyst Jason Butler of JMP Securities reiterated a Buy rating on Prothena (PRTA – Research Report), retaining the price target of ...

Hello, and welcome to Acumen Pharmaceuticals Q3 2024 conference call and webcast. At this time, all participants are in a listen-only mode. As of the speaker's presentation, there will be a ...

The drug works by removing accumulated amyloid beta proteins in the brain, slowing the progress of the disease. Those ...

single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.

The positive rate of amyloid beta protein, indicating the risk of Alzheimer's disease-causing substance accumulation, was ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...